Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharma
STAT+

Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases

  • Adam Feuerstein

By Adam Feuerstein Nov. 21, 2022

Reprints
Merck logo
Mel Evans/AP

Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs that target bone marrow diseases to its research pipeline.

The all-cash deal values Imago at $36 per share, or a 107% premium from its closing price on Friday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Create a display name to comment

This name will appear with your comment

Buyer’s remorse: How a Medicare Advantage business is strangling…
Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders
Experts weigh in on potential health hazards posed by…
Experts weigh in on potential health hazards posed by chemicals in Ohio train derailment
23andMe had devastating news about my health. I wish…
23andMe had devastating news about my health. I wish a person had delivered it
Takeda autoimmune therapy shows effectiveness in key trial
Takeda autoimmune therapy shows effectiveness in key trial
Moderna CEO made $398 million in 2022, but still…
Moderna CEO made $398 million in 2022, but still pledges to give most to charity
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings

Recommended Stories